WuXi Biologics Executive and Leadership Team

Jimmy Li, the Chief Executive Officer at WuXi Biologics, directs the overarching corporate strategy and global expansion initiatives. Overseeing the entire organizational structure, the Chief Executive Officer ensures alignment between internal research capabilities and the evolving demands of the international biopharmaceutical sector. This leadership role involves cultivating strategic partnerships across North America, Europe, and Asia to solidify market presence. By optimizing operational workflows, Jimmy Li directly impacts the company's ability to provide end-to-end drug development solutions. Li maintains rigorous oversight of long-term growth objectives while fostering a culture of innovation within the integrated technology platforms. Through constant engagement with the Board, the Chief Executive Officer secures the necessary resources to scale manufacturing capacity and enhance service delivery. Ultimately, Li drives the mission to transform the biologics industry through advanced, accessible, and high-quality development services.

Ming Tu, the Chief Financial Officer & Executive Vice President at WuXi Biologics, manages the fiscal health and capital allocation strategies of the organization. Overseeing global financial reporting and investor relations, the Chief Financial Officer & Executive Vice President ensures transparency and sustainable growth across all international business units. This leadership role involves evaluating investment opportunities in new laboratory facilities and manufacturing infrastructure to support the company's rapid scaling. By implementing robust financial controls, Ming Tu directly impacts the operational efficiency of the integrated drug development platforms. Tu coordinates with other C-suite leaders to align budgetary priorities with long-term strategic goals. Through meticulous risk management and capital planning, the Chief Financial Officer & Executive Vice President secures the financial stability required for continuous innovation. Ultimately, Tu maintains the fiscal integrity necessary to support the company's mission of accelerating global biologics development.

Jijie Gu, the Chief Scientific Officer, President of Global Biologics Research at WuXi Biologics, directs the scientific vision and research initiatives across the global organization. Overseeing the discovery and development of novel biologics, the Chief Scientific Officer, President of Global Biologics Research ensures the application of rigorous scientific standards to all client projects. This leadership role involves managing large-scale research teams focused on antibody engineering and protein expression to solve complex therapeutic challenges. By advancing the company's proprietary technology platforms, Jijie Gu directly impacts the success rates of drug development programs. Gu coordinates with internal R&D departments to foster innovation and maintain scientific excellence in the competitive global market. Through the oversight of research methodologies, the Chief Scientific Officer, President of Global Biologics Research secures the intellectual property and scientific breakthroughs necessary for long-term growth. Ultimately, Gu drives the company's commitment to scientific leadership in the biologics sector.

Sherry Gu, the Executive Vice President & Chief Technology Officer at WuXi Biologics, architects the technological infrastructure and digital transformation strategies for the company. Overseeing the integration of advanced manufacturing technologies and automated systems, the Executive Vice President & Chief Technology Officer ensures the delivery of high-quality biologics development services. This leadership role involves driving the adoption of cutting-edge digital tools to streamline complex R&D processes across global operations. By optimizing technical workflows, Sherry Gu directly impacts the speed and precision of drug development cycles. Gu collaborates with scientific teams to implement innovative solutions that enhance production capacity and service reliability. Through the continuous evaluation of emerging technologies, the Executive Vice President & Chief Technology Officer maintains the company's competitive edge in the biopharmaceutical market. Ultimately, Gu secures the technological foundation required to support the company's mission of providing world-class, integrated development platforms.